Schrodinger, Inc. revenue
Schrodinger, Inc.'s revenue was $256m in fiscal 2025, up 23.3% on the year before. Since fiscal 2019 ($85.5m) it has grown at a compound 20.0% a year. Over the last twelve months it was $259m.
Revenue history
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 86 | 108 | 138 | 181 | 217 | 208 | 256 | 259 |
| Growth on the year before | — | +26.4% | +27.6% | +31.2% | +19.7% | −4.2% | +23.3% | — |
| Gross profit | 49 | 63 | 66 | 101 | 141 | 132 | 143 | 147 |
| Gross margin | 57.4% | 58.7% | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% | 56.9% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Software | $200M | 78.0% | ▲ 10.6% |
| Drug Discovery | $56.4M | 22.0% | ▲ 107.4% |
| Line of business | Revenue | YoY |
|---|---|---|
| Software Products and Services | $200M | ▲ 10.6% |
| Revenue From Contract With Customer Before Software Contribution | $184M | ▲ 6.5% |
| On Premise Software | $101M | ▼ 2.5% |
| Drug Discovery | $56.4M | ▲ 107.4% |
| Drug Discovery Services | $54.8M | ▲ 117.8% |
| Hosted Software | $45.1M | ▲ 28.0% |
| Maintenance | $27.3M | ▲ 17.2% |
| Professional Services | $9.6M | ▼ 1.5% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $153M | 59.8% | ▲ 33.2% |
| EMEA | $75.2M | 29.4% | ▲ 14.5% |
| APAC | $26.2M | 10.2% | ▲ 1.5% |
| Outside the US | $1.6M | 0.6% | ▲ 28.2% |
From Schrodinger, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Schrodinger, Inc. | $259m | 8.9% | 10.2% |
| Mesa Laboratories Inc | $250m | 3.0% | 4.4% |
| Maravai Lifesciences Holdings, Inc. | $209m | -5.0% | -27.3% |
| Fulgent Genetics, Inc. | $324m | 6.8% | 1.8% |
| Cytek Biosciences, Inc. | $207m | 5.4% | 5.6% |
| Castle Biosciences Inc | $357m | 3.2% | 28.7% |
Compare with peers
- Mesa Laboratories Inc revenue
- Maravai Lifesciences Holdings, Inc. revenue
- Fulgent Genetics, Inc. revenue
- Cytek Biosciences, Inc. revenue
- Castle Biosciences Inc revenue
Head to head: MLAB vs SDGRMRVI vs SDGRFLGT vs SDGRCSTL vs SDGR
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies